Skip to main content

Advertisement

SpringerLink
Log in

Clinical, Ethical, and Socioeconomic Considerations for Prescription Drug Use During Pregnancy in Women Suffering From Chronic Diseases

  • Special Populations: Review
  • Published:
Therapeutic Innovation & Regulatory Science Aims and scope Submit manuscript

Abstract

The increasing proportion of women conceiving later in life, associated with the higher probability of contracting a chronic disease, highlights an increasing need to understand the impact of drug use for chronic diseases pre- and postpartum. In this study, the authors report the results of systematic reviews of drug use during pregnancy by focusing on pregnant women with a chronic disease, specifically, epilepsy, rheumatoid arthritis (RA), or schizophrenia. The authors studied the clinical impact of drug use in these chronic diseases on the mother and fetus, as well as the ethical issues and socioeconomic impact of drug use during pregnancy for women with these conditions. The results indicate that treatment discontinuation in epilepsy and schizophrenia can lead to serious adverse effects, whereas pregnancy can have an ameliorating effect on RA symptoms. Delivery and neonatal complications were associated with the use of older generation drugs across the 3 diseases. Newer generation drugs were deemed safer but more expensive. Ethical considerations for physicians and patients involved mainly the potential risks of drug use for the fetus. In conclusion, treatment guidelines need to be developed in the future; additionally, better insight into the economics of pregnancy for women with chronic diseases will improve value for money in obstetric care.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Organisation for Economic Co-operation and Development. Society at a Glance 2009: OECD Social Indicators. Paris, France: OECD Publishing; 2009.

    Google Scholar 

  2. Organisation for Economic Co-operation and Development. Mean Age of Mothers at First Child Birth. OECD Family Database. Paris, France: OECD Social Policy Division; 2012.

    Google Scholar 

  3. World Health Organization. Global Status Report on Noncommunicable Diseases 2010. Geneva, Switzerland: World Health Organization; 2011.

    Google Scholar 

  4. Golding A, Haque UJ, Giles JT. Rheumatoid arthritis and reproduction. Rheum Dis Clin N Am. 2007;33(2):319–343.

    Article  Google Scholar 

  5. Beghi E. Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines. Lancet Neurol. 2004;3(10):618–621.

    Article  CAS  PubMed  Google Scholar 

  6. Grimaccia F, Kanavos P. Treating epilepsy during pregnancy: a systematic literature review of the impact of drug treatment on mother and foetus. LSE Health Working Paper Series in Health Policy and Economics. Working Paper 39. London: London School of Economics.

  7. Østensen M, Förger F. Management of RA medications in pregnant patients. Nat Rev Rheumatol. 2009;5(7):382–390.

    Article  PubMed  Google Scholar 

  8. Toh S, Li Q, Cheetham TC, et al. Prevalence and trends in the use of antipsychotic medications during pregnancy in the US, 2001–2007: a population-based study of 585,615 deliveries. Arch Womens Ment Health. 2013;16(2):149–157.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Grepstad M, Tzouma V, Grimaccia F, Kanavos P. Treating schizophrenia during pregnancy: a systematic literature review on the impact of drug treatment on mother and foetus. LSE Health Working Paper Series in Health Policy and Economics. Working Paper 41. London: London School of Economics.

  10. Viinikainen K, Heinonen S, Eriksson K, Kälviäinen R. Community-based, prospective, controlled study of obstetric and neonatal outcome of 179 pregnancies in women with epilepsy. Epilepsia. 2006;47(1):186–192.

    Article  PubMed  Google Scholar 

  11. Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising? Results from Olmsted County, Minnesota, 1955–2007. Arthritis Rheum. 2010;62(6):1576–1582.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Black DW, Andreasen NC. Introductory Textbook of Psychiatry. Arlington, Virginia: American Psychiatric Publishing; 2011.

    Google Scholar 

  13. Mecacci F, Pieralli A, Bianchi B, Paidas MJ. The impact of autoimmune disorders and adverse pregnancy outcome. Semin Perinatol. 2007;31(4):223–226.

    Article  PubMed  Google Scholar 

  14. Castle D, Sham P, Murray R. Differences in distribution of ages of onset in males and females with schizophrenia. Schizophr Res. 1998;33(3):179–183.

    Article  CAS  PubMed  Google Scholar 

  15. Wyllie E, Cascino GD, Gidal E, Goodkin HP, eds. Wyllie’s Treatment of Epilepsy: Principles and Practice. Philadelphia: Lippincott Williams & Wilkins; 2012.

    Google Scholar 

  16. Tzouma V, Grepstad M, Kanavos P. Treating rheumatoid arthritis during pregnancy: a systematic literature review of the impact of drug treatment on mother and foetus. LSE Health Working Paper Series. Working Paper 40. London: London School of Economics.

  17. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006–1012.

    Article  PubMed  Google Scholar 

  18. NHS Centre for Reviews and Dissemination. Systematic Reviews: CRD’s Guidance for Undertaking Reviews in Health Care. York, United Kingdom: University of York, NHS Centre for Reviews and Dissemination; 2008.

    Google Scholar 

  19. Doherty M. What value case reports? Ann Rheum Dis. 1994;53(1):1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Østensen M, Fuhrer L, Mathieu R, Seitz M, Villiger PM. A prospective study of pregnant patients with rheumatoid arthritis and ankylosing spondylitis using validated clinical instruments. Ann Rheum Dis. 2004;63(10):1212–1217.

    Article  PubMed  PubMed Central  Google Scholar 

  21. De Man YA, Dolhain RJ, van de Geijn FE, Willemsen SP, Hazes JM. Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Rheum. 2008;59(9):1241–1248.

    Article  PubMed  Google Scholar 

  22. Förger F, Vallbracht I, Helmke K, Villiger PM, Østensen M. Pregnancy mediated improvement of rheumatoid arthritis. Swiss Med Wkly. 2012;142:w13644.

    PubMed  Google Scholar 

  23. El-Taweel El-Ebyary MM, El-Motayam AS, Agban EL. Seizures profile during pregnancy in women with epilepsy. Egypt J Neurol Psychiatry Neurosurg. 2009;46(1):119–127.

    Google Scholar 

  24. Hironaka M, Kotani T, Sumigama S, et al. Maternal mental disorders and pregnancy outcomes: a clinical study in a Japanese population. J Obstet Gynaecol Res. 2011;37(10):1283–1289.

    Article  PubMed  Google Scholar 

  25. US Food and Drug Administration. Information for healthcare professionals: risk of neural tube birth defects following prenatal exposure to valproate. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm192649.htm. Accessed April 9, 2015.

  26. Epilepsy Research UK. Leaving epilepsy untreated during pregnancy “can be dangerous.” Available at: http://www.epilepsyresearch.org.uk/leaving-epilepsy-untreated-during-pregnancy-can-be-dangerous/. Accessed April 9, 2015.

  27. Coppola D, Russo LJ, Kwarta RF Jr., Varughese R, Schmider J. Evaluating the postmarketing experience of risperidone use during pregnancy. Drug Safety. 2007;30(3):247–264.

    Article  CAS  PubMed  Google Scholar 

  28. Almarzouqi M, Scarsbrook D, Klinkhoff A. Gold therapy in women planning pregnancy: outcomes in one center. J Rheumatol. 2007;34(9):1827–1831.

    PubMed  Google Scholar 

  29. Cassina M, Johnson DL, Robinson LK, et al. Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis Rheum. 2012;64(7):2085–2094.

    Article  CAS  PubMed  Google Scholar 

  30. Chambers CD, Johnson DL, Robinson LK, et al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum. 2010;62(5):1494–1503.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Mawer G, Briggs M, Baker GA, et al. Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study. Seizure. 2010;19(2):112–119.

    Article  CAS  PubMed  Google Scholar 

  32. Vajda FJ, O’Brien TJ, Hitchcock A, Graham J, Lander C. The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months. J Clin Neurosci. 2003;10(5):543–549.

    Article  CAS  PubMed  Google Scholar 

  33. Østensen M, von Esebeck M, Villiger PM. Therapy with immunosuppressive drugs and biological agents and use of contraception in patients with rheumatic disease. J Rheumatol. 2007;34(6):1266–1269.

    PubMed  Google Scholar 

  34. Hajdyla-Banaś I, Banas T, Rydz-Stryszowska I, et al. Pregnancy course and neonatal outcome after exposure to leflunomide—2 cases report and review of literature. Przegl Lek. 2009;66(12):1069–1071.

    PubMed  Google Scholar 

  35. Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000;62(6):385–392.

    Article  CAS  PubMed  Google Scholar 

  36. Sinha A, Patient C. Rheumatoid arthritis in pregnancy: successful outcome with anti-TNF agent (etanercept). J Obstet Gynaecol. 2006;26(7):689–691.

    Article  CAS  PubMed  Google Scholar 

  37. Umeda N, Ito S, Hayashi T, Goto D, Matsumoto I, Sumida T. A patient with rheumatoid arthritis who had a normal delivery under etanercept treatment. Inter Med. 2010;49(2):187–189.

    Article  Google Scholar 

  38. Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117(5):1499–1506.

    Article  CAS  PubMed  Google Scholar 

  39. Dudzinski DM, Sullivan M. When agreeing with the patient is not enough: a schizophrenic woman requests pregnancy termination. Gen Hosp Psychiatry. 2004;26(6):475–480.

    Article  PubMed  Google Scholar 

  40. Kim SW, Kim KM, Kim JM, et al. Use of long-acting injectable risperidone before and throughout pregnancy in schizophreniai. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):543–545.

    Article  CAS  PubMed  Google Scholar 

  41. Yaeger D, Smith H, Altshuler L. Atypical antipsychotics in the treatment of schizophrenia during pregnancy and the postpartum. Am J Psychiatry. 2006;163(12):2064–2070.

    Article  PubMed  Google Scholar 

  42. Ružić K, Dadić-Hero E, Knez R, Medved P, Petrić D. Pregnancy and atypical antipsychotics. Psychiatr Danub. 2009;21(3):368–370.

    PubMed  Google Scholar 

  43. Vučić-Peitl M, Petrić D, Peitl V. Ziprasidone as a possible cause of cleft palate in a newborn. Psychiatr Danub. 2010;22(1):117–119.

    Google Scholar 

  44. Janjić V, Milovanovic D, Ruzic-Zecevic D, Loncar D, et al. Zuclopenthixol decanoate in pregnancy: Successful outcomes in two consecutive off springs of the same mother. Vojnosanitetski Pregled. 2013;70(5):526–529.

    Article  PubMed  Google Scholar 

  45. American College of Obstetricians and Gynecologists. Use of Psychiatric Medications During Pregnancy and Lactation. ACOG Practice Bulletin No. 92. Washington, District of Columbia: American College of Obstetricians and Gynecologists; 2008.

    Google Scholar 

  46. Coverdale JH, McCullough LB, Chervenak FA. Assisted and surrogate decision making for pregnant patients who have schizophrenia. Schizophr Bull. 2004;30(3):659–664.

    Article  PubMed  Google Scholar 

  47. Oates M. Psychiatric services for women following childbirth. Int Rev Psychiatry. 1996;8(1):87–98.

    Article  Google Scholar 

  48. Muqtadir S, Hamann MW, Molnar G. Management of psychotic pregnant patients in a medical-psychiatric unit. Psychosomatics. 1986;27(1):31–33.

    Article  CAS  PubMed  Google Scholar 

  49. Chambers CD, Polifka JE, Friedman JM. Drug safety in pregnant women and their babies: Ignorance not bliss. Clin Pharmacol Ther.2008;83(1):181–183.

    Article  CAS  PubMed  Google Scholar 

  50. Charlton RA, Weil JG, Cunnington MC, Ray S, de Vries CS. Comparing the General Practice Research Database and the UK Epilepsy and Pregnancy Register as tools for postmarketing teratogen surveillance: anticonvulsants and the risk of major congenital malformations. Drug Saf. 2011;34(2):157–171.

    Article  PubMed  Google Scholar 

  51. Dewulf L. Medicines in pregnancy—women and children first? Time for a coalition to address a substantial patient need. Ther Innov Regulat Sci. 2013;47(5):528–532.

    Article  Google Scholar 

  52. Clemow DB, Dewulf L, Michaels DL, et al. A proposed framework to address needs of clinical data for informed medication use in pregnancy. Ther Innov Regulat Sci. 2014;48(2):145–154.

    Article  Google Scholar 

  53. US Food and Drug Administration. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation final labeling rule. Available at: https://www.federalregister.gov/articles/2014/12/04/2014-28241/content-and-format-of-labeling-for-human-prescription-drug-and-biological-products-requirements-for. Accessed April 10, 2015.

  54. Vajda FJE, Lander CM, Hitchcock A, et al. Changing Australian prescribing patterns for antiepileptic drugs in pregnancy and their possible consequences. J Clin Neurosci. 2007;14(7):611–617.

    Article  CAS  PubMed  Google Scholar 

  55. Jentink J, Loane MA, Dolk H, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med. 2010;362(23):2185–2193.

    Article  CAS  PubMed  Google Scholar 

  56. Vajda FJE, Graham JE, Hitchcock AA, O’Brien TJ, Lander CM, Eadie MJ. Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure. 2010;19(9):558–561.

    Article  CAS  PubMed  Google Scholar 

  57. Physicians Committee for Responsible Medicine, ed. Birth Defect Statistics. Washington, District of Columbia: Physicians Committee for responsible Medicine; 2014.

    Google Scholar 

  58. Russell RB, Green NS, Steiner CA, et al. Cost of hospitalization for preterm and low birth weight infants in the United States. Pediatrics. 2007;120(1):e1–e9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. LSE Health, Cowdray House, London School of Economics and Political Science, Houghton Street, London, WC2A 2AE, UK

    Victoria Tzouma MSc, Mari Grepstad MSc, Federico Grimaccia MD & Panos Kanavos PhD

  2. Department of Social Policy, London School of Economics and Political Science, London, UK

    Panos Kanavos PhD

Authors
  1. Victoria Tzouma MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mari Grepstad MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Federico Grimaccia MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Panos Kanavos PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Panos Kanavos PhD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tzouma, V., Grepstad, M., Grimaccia, F. et al. Clinical, Ethical, and Socioeconomic Considerations for Prescription Drug Use During Pregnancy in Women Suffering From Chronic Diseases. Ther Innov Regul Sci 49, 947–956 (2015). https://doi.org/10.1177/2168479015589820

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/2168479015589820

Keywords

Search

Navigation